Centocor gets another expanded approval for Remicade
The extended approval is based on one-year data from a double-blind, placebo-controlled trial named IMPACT 2 and two-year data from a double-blind, placebo-controlled trial named IMPACT. Findings from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.